肥満管理のための薬剤療法 - GLP-1受容体アゴニストベースの治療法の役割を強調する

Bruce A Warden¹, Paul Barton Duell², John D Bucheit³

¹Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA (Drs Warden, Duell, and Purnell); General Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA (Dr Warden).

Journal of clinical lipidology

|February 18, 2026

まとめ

グルカゴンのようなペプチド-1受容体アゴニスト (GLP-1RA) は,肥満に対する効果的な薬です. これらの治療は,疾患を修正する結果を提供し,肥満とその合併症を管理するのに役立ちます.

科学分野:

エンドクリノロジーエンドクリノロジー
薬理学薬理学とは
メタボリック疾患

背景:

肥満は,流行率が増加し,健康に重大なリスクをもたらす複雑な慢性疾患です.
歴史的に見ると,ライフスタイルの変化を超えた肥満治療は,未充分利用と汚名に直面しました.
効果的な管理には,ライフスタイル,薬剤療法,手術を含むマルチモダルのアプローチが必要です.

研究の目的:

成人における肥満薬 (OM) の使用をレビューする.
グルカゴン型ペプチド-1受容体アゴニスト (GLP-1RA) と,GLP-1RA/グルコース依存型インスリン型ポリペプチド (GIP) のダブルアゴニストに焦点を当てること.
患者の選択,治療開始,定位,利益,リスク,コストを検証する.

主な方法:

肥満の薬物療法に関する現在の文献のレビュー.
GLP-1 RAとGLP-1 RA/GIP二重受容体アゴニストを重視しています.
臨床実務ガイドラインと新興証拠の分析.

主要な成果:

GLP-1 RAsは,肥満に対する非常に効果的な薬剤療法です.
これらの薬剤は,好ましい安全性および耐受性プロファイルを示しています.
GLP-1 RAの使用には,疾患を変化させる重要なアウトカムが関連しています.

結論:

GLP-1 RAsは,肥満とその合併症の管理に役立つ貴重なツールです.
これらの薬は,肥満の増加率と関連する健康問題を軽減するのに役立ちます.
広範な採用のために,さらなる研究とアクセスの検討は重要です.

キーワード:

アディポシティー (肥満) とはグルカゴン類ペプチド-1受容体アゴニストである.肥満管理について肥満の薬剤は,肥満に対する薬剤です.薬剤療法薬剤療法について

さらに関連する動画

04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.6K

03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

5.2K

関連する概念動画

01:24

Glucagon-like Receptor Agonists

1.0K

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

1.0K

01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

302

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...

302

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

702

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

702

01:15

Diabetes: Management and Pharmacotherapy

1.1K

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

1.1K

01:06

Oral Hypoglycemic Agents: Glinides

715

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

715

01:23

Dipeptidyl Peptidase 4 Inhibitors

752

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

752

関連する実験動画